Gene Therapy for Colon Cancer Using Targeted Enzyme
Author Information
Author(s): D Oosterhoff, R M Overmeer, M de Graaf, I H van der Meulen, G Giaccone, V W van Beusechem, H J Haisma, H M Pinedo, W R Gerritsen
Primary Institution: VU University Medical Center
Hypothesis
Can a targeted, secreted form of carboxylesterase enhance the effectiveness of CPT-11 in treating colon cancer?
Conclusion
The adenoviral vector Ad.C28-sCE2 can effectively convert CPT-11 into its active form, leading to increased toxicity against colon cancer spheroids.
Supporting Evidence
- Ad.C28-sCE2-transduced colon carcinoma cells expressed and secreted active carboxylesterase.
- Treatment with CPT-11 resulted in growth inhibition comparable to treatment with its active form, SN-38.
- The study demonstrated that the fusion protein could bind to untransduced neighboring cells.
Takeaway
Scientists created a special virus that helps a medicine work better against colon cancer by targeting it directly to the cancer cells.
Methodology
The study used a three-dimensional colon cancer spheroid model to test the effectiveness of the adenoviral vector Ad.C28-sCE2 in sensitizing cancer cells to CPT-11.
Limitations
The study primarily used in vitro models, which may not fully replicate in vivo conditions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website